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Original articleLKB1 and AMPKa1 are required in pancreatic
alpha cells for the normal regulation of glucagon
secretion and responses to hypoglycemiaGao Sun 1, Gabriela da Silva Xavier 1, Tracy Gorman 2, Claire Priest 2, Antonia Solomou 1, David J. Hodson 1,
Marc Foretz 3,4,5, Benoit Viollet 3,4,5, Pedro-Luis Herrera 6, Helen Parker 7, Frank Reimann 7, Fiona M. Gribble 7,
Stephanie Migrenne 8, Christophe Magnan 8, Anna Marley 2, Guy A. Rutter 1,*ABSTRACT
Aims/Hypothesis: Glucagon release from pancreatic alpha cells is required for normal glucose homoeostasis and is dysregulated in both Type 1
and Type 2 diabetes. The tumour suppressor LKB1 (STK11) and the downstream kinase AMP-activated protein kinase (AMPK), modulate cellular
metabolism and growth, and AMPK is an important target of the anti-hyperglycaemic agent metformin. While LKB1 and AMPK have emerged
recently as regulators of beta cell mass and insulin secretion, the role of these enzymes in the control of glucagon production in vivo is unclear.
Methods: Here, we ablated LKB1 (aLKB1KO), or the catalytic alpha subunits of AMPK (aAMPKdKO, -a1KO, -a2KO), selectively in w45% of
alpha cells in mice by deleting the corresponding ﬂox’d alleles with a preproglucagon promoter (PPG) Cre.
Results: Blood glucose levels in male aLKB1KO mice were lower during intraperitoneal glucose, aminoimidazole carboxamide ribonucleotide
(AICAR) or arginine tolerance tests, and glucose infusion rates were increased in hypoglycemic clamps (p< 0.01). aLKB1KO mice also displayed
impaired hypoglycemia-induced glucagon release. Glucose infusion rates were also elevated (p < 0.001) in aAMPKa1 null mice, and
hypoglycemia-induced plasma glucagon increases tended to be lower (p ¼ 0.06). Glucagon secretion from isolated islets was sensitized to the
inhibitory action of glucose in aLKB1KO, aAMPKdKO, and -a1KO, but not -a2KO islets.
Conclusions/Interpretation: An LKB1-dependent signalling cassette, involving but not restricted to AMPKa1, is required in pancreatic alpha
cells for the control of glucagon release by glucose.
 2015 Published by Elsevier GmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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Glucagon, secreted by the pancreatic islet alpha cell as blood glucose
levels fall, is the key anti-hypoglycemic hormone in mammals, acting
as a powerful stimulus for hepatic glucose production [1]. Impaired
glucagon release is associated with the episodes of hypoglycemia
frequently reported in Type 1 and advanced Type 2 diabetic (T2D)
patients treated with insulin or sulphonylureas [2]. On the other hand,
elevated circulating glucagon levels contribute to the chronic increase
in blood glucose levels characteristic of T2D [1].
Lowered blood glucose levels stimulate glucagon release through
multiple mechanisms including changes in parasympathetic [3] and
sympathetic tone [4], increases in circulating adrenaline levels [5], as
well as through effects of glucose on pancreatic alpha cells [6]. The
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www.molecularmetabolism.comeffect of glucose [7,8] and indirect effects of g-amino butyric acid
(GABA) [9,10] and insulin [7,11] released from neighbouring beta cells
have all been invoked as regulators of glucagon secretion. Roles for
released Zn2þ ions have also been proposed [7,12e14].
AMP-activated protein kinase (AMPK) is a heterotrimeric complex
comprising a, b and g subunits that serves as a master energy sensor
[15], highly sensitive to intracellular ATP:AMP [15] and ATP:ADP ratios
[16]. Liver kinase B1 (LKB1), also called STK11, is a tumour sup-
pressor whose inactivation leads to Peutz-Jegers syndrome [17],
characterized by hamartomatous polyps and an increased risk of all
cancers. LKB1 phosphorylates at least 13 different protein kinases
including AMPK. LKB1 (and alternative protein kinases including
calmodulin kinase kinase b [18,19] and transforming growth factor b-
activated kinase-1, TAK1) [20], phosphorylate AMPK catalytic a-sub-
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Original articlealtered occupancy by AMP and/or ADP of sites in the g-subunit, leads
to conformational changes that render T172 in the a-subunit less
susceptible to dephosphorylation [16] by protein phosphatases [21].
Activated AMPK then phosphorylates a range of downstream metabolic
targets to promote ATP synthesis and inhibit ATP consumption [15].
Through the use of pharmacological AMPK activators and inhibitors
[22], we have previously provided evidence that AMPK is a negative
regulator of insulin secretion from pancreatic beta cells [23,24].
Furthermore, activation of AMPK by metformin is associated with
enhanced beta cell apoptosis [25]. Correspondingly, mice deleted
selectively in the beta cell for LKB1 display beta cell hyperplasia and
markedly enhanced insulin release [26e28]. By contrast, and unex-
pectedly, deletion of both AMPK catalytic subunits (a1 and a2) from
beta cells causes impaired insulin secretion and glucose intolerance
in vivo [29,30], possibly as a result of rat insulin promoter-2 (RIP2)-
Cre-mediated recombination in the brain [31].
We have also recently provided evidence from in vitro studies that
AMPK is involved in the regulation of glucagon release. Thus, activation
of AMPK stimulated glucagon release from clonal aTC1-9 cells and
mouse pancreatic islets, while a dominant-negative form of the kinase
blocked the stimulatory effects of low glucose [22]. However, neither
the role of LKB1 nor that of individual AMPK isoforms in controlling
glucagon secretion has been examined in vivo.
Here, we have generated mice deleted for LKB1 (aLKB1KO), and for
one (AMPKa1KO, -a2KO) or both (aAMPKdKO) AMPKa catalytic
subunits selectively in pancreatic alpha cells using preproglucagon
(PPG)-Cre driven recombination. We show that LKB1 signalling, at least
partly mediated via AMPKa1, is essential for the normal stimulation of
glucagon secretion at low glucose levels both in vitro and in vivo.
Moreover, and in marked contrast to its action in the beta cell, we
show that LKB1 plays a limited if any role in the control of alpha cell
size or total alpha cell mass [26e28].
2. METHODS
2.1. Generation of mutant mice lacking LKB1 selectively in
pancreatic alpha cells
Mice heterozygous for ﬂox’d alleles of the Lkb1/Stk11 gene (mixed
FVB/129S6 and C57BL/6 background) [32] were obtained from the
Mouse Models of Human Cancer Consortium (MMHCC) (www.nih.gov/
science/models/mouse/resources/hcc.html) and backcrossed with
C57/B6 mice four times. These animals were then bred against PPG-
Cre expressing mice [33] and the resulting heterozygous offspring
were inter-crossed as siblings to generate aLKB1KO mice (Lkb1ﬂ/ﬂ,
Cre positive). aLKB1KO mice were further bred with Lkb1ﬂ/ﬂ mice to
generate littermate controls (Lkb1ﬂ/ﬂ). It should be noted that the PPG-
Cre transgene is not reported to exert effects on glucagon secretion or
glucose homoeostasis [34] or to lead to signiﬁcant recombination in
extra-pancreatic tissues [11]. aLKB1KO mice and littermate controls
were born at the expected Mendelian ratios.
2.2. Generation of mutant mice selectively lacking AMPK a1 and
a2 in pancreatic alpha cells
Mice homozygous for Ampka1ﬂ/ﬂ were crossed with mice heterozy-
gous for Ampka2ﬂ/þ. The resulting double heterozygotes (Ampka1ﬂ/þ,
a2ﬂ/þ) were crossed with PPG-Cre-expressing animals [33] to
generate triple heterozygous mice (Ampka1ﬂ/þ, a2ﬂ/þ, Cre positive).
The latter were then bred with mice homozygous for both ﬂox’d
Ampka1 and a2 alleles (Ampka1ﬂ/ﬂ, a2ﬂ/ﬂ) to produce aAMPKdKO
mice (Ampka1ﬂ/ﬂ, a2ﬂ/ﬂ, Cre positive). aAMPKdKO mice were further278 MOLECULAR METABOLISM 4 (2015) 277e286  2015 Published by Elsecrossed with Ampka1ﬂ/ﬂ, a2ﬂ/ﬂ mice to generate littermate controls
(Ampka1ﬂ/ﬂ, a2ﬂ/ﬂ). All mice were kept on a C57/B6 background.
2.3. Generation of mice selectively expressing RFP in pancreatic
alpha cells
Mice heterozygous for Rosa26tdRFP [35] were crossed with mice
heterozygous for PPG-Cre to generate double heterozygous mice.
2.4. Mouse maintenance and diet
Animals were housed two to ﬁve per individually ventilated cage in a
pathogen-free facility with 12 h light/dark cycle and had free access to
standard mouse chow diet. All in vivo procedures described were
performed at the Imperial College Central Biomedical Service and
approved by the UK Home Ofﬁce according to the Animals (Scientiﬁc
Procedures) Act 1986 of the United Kingdom (PPL 70/7349).
2.5. Glucose, insulin, AICAR and arginine tolerance tests
Intraperitoneal glucose and insulin tolerance tests were performed as
previously described [28,30]. For AICAR tolerance, mice fasted for
16 h (water allowed) were intraperitoneally injected with 1.75 g
AICAR/kg (Toronto Research Chemicals, North York, Canada). Blood
(2e4 ml) from the tail vein was obtained at 0, 20, 40, 60, 90 and
120 min after injection [36]. Blood glucose levels were measured
with an automatic glucometer (Accuchek; Roche, Burgess Hill, UK).
For arginine tolerance, mice fasted for 16 h (water allowed) were
intraperitoneally injected with 3 g/kg L-arginine (pH 7.4; Arginine
hydrochloride from Sigma) [11]. Blood (50 ml) from the tail vein was
collected at 0, 10 and 30 min after injection into EDTA coated tubes
containing 1 ml DPP IV inhibitor (ﬁnal concentration: 100 mmol/l;
Millipore, Watford, UK). Plasma insulin and glucagon levels were
measured with an ultrasensitive mouse insulin ELISA kit (Mercodia,
Uppsala, Sweden) [37] and a glucagon radioimmunoassay kit with a
competitive 125I labelled glucagon (Millipore, Watford, UK) [7]
respectively. Experiments were performed on mice aged 8e12
weeks.
2.6. Hyperinsulinemic-hypoglycemic clamp
Nine week-old male mice were implanted with catheters in the right
jugular vein under general ketamine (100 mg/kg)/xylazine (10 mg/kg)
anaesthesia. Catheters were ﬂushed daily with saline containing
heparin (0.4U/100 ml). Mice were housed individually in separate
cages for post-surgery recovery. On the day of the clamp study, mice
were starved for ﬁve hours before catheters were connected onto
infusion tubing. Mice were infused with bolus insulin (0.033U) at an
infusion rate of 30 ml/min for 5 min. To maintain blood glucose levels
close to 2.7e3.3 mmol/l, insulin (0.6 U/kg/h) were infused for
120 min, during which 20% glucose was co-infused with adjustable
infusion rates. Blood was collected from tail veins for measurement of
glucose levels every 10 or 20 min.
2.7. Other methods
Please see Supplementary Materials and Methods.
2.8. Statistical analysis
Signiﬁcance was tested using unpaired or paired Student’s two-tailed
t-tests with Bonferroni post-tests for multiple comparisons, or two-way
ANOVA with Sidak post-doc tests as required. Analysis was performed
using Excel (Microsoft) and Graphpad Prism 4.0 (Graphpad Software).
p < 0.05 was considered signiﬁcant and values represent
mean  SEM.vier GmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
www.molecularmetabolism.com
3. RESULTS
3.1. Generation of mice deleted selectively in the pancreatic alpha
cell for LKB1 or AMPKa-subunits
To assess the likely efﬁciency and speciﬁcity of recombination in alpha
cells, we ﬁrst crossed mice bearing a tandem dimer red ﬂuorescentFigure 1: Generation of alpha cell speciﬁc LKB1 and AMPK a subunit(s) KO mice (A) (i) Re
antibodies against RFP (1:100) and either glucagon (1:2000; green) or insulin (1:200; green
to calculate the percentage of cells positive for glucagon or insulin and co-expressing RFP
islets, brain stems, hypothalamus and intestines. The product sizes were 864 and 300b
staining of pancreatic sections using mouse anti-glucagon (1:2000; red) and rabbit anti-LKB
Total AMPK activity in islets of aLKB1KO (D), aAMPK KOs (E) and their wild type littermate
48e72 h, were further incubated with RPMI media containing 3 mmol/l glucose for 1 h b
between groups using unpaired two-tailed Student’s t-tests.
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control cassette (Rosa26tdRFP) [35] against animals bearing Cre
recombinase under the control of a 0.6 kb fragment of the rat pre-
proglucagon promoter (PPG) [38]. This led to almost exclusive
expression of PPG-Cre in glucagon-positive pancreatic alpha cells, of
which w45% were positive for tdRFP (Figure 1A(i)). Expression inpresentative immunostaining of pancreatic islets isolated from PPG-Cre:RFP mice using
). Nuclei are shown by DAPI (blue) staining. (ii) Images of stained islets (5e8) were used
. (B) RT-PCR analysis of deletion of exon 3e6 on LKB1 transcript levels in pancreatic
p for the ﬂox’d and null alleles, respectively. (C) Representative immunoﬂuorescence
1 (1:100; green) antibodies. Nuclei are shown with DAPI (blue). Scale bar, 75 mm. (D,E)
control mice (WT). Islets incubated with RPMI media containing 10 mmol/l glucose for
efore analysis. Data are expressed as means  SEM; n ¼ 4, *p < 0.05, **p < 0.01
article under the CC BY license (http://creativecommons.org/licenses/by/3.0/). 279
Original articleother cell types was below the limit of reliable detection (<3% of
insulin-positive cells showed weak staining, likely attributable to
background ﬂuorescence; Figure 1A(ii)).
We next generated mice deleted for LKB1 in the alpha cell compart-
ment (aLKB1KO) by crossing animals in which exons 3e6 of the Lkb1
gene were ﬂanked with LoxP sites [32] with PPG-Cre mice [33]. The
excision of exons 3e6 mediated by Cre was observed in pancreatic
islets of aLKB1KO mice, but not evident in other preproglucagon-
expressing tissues, such as brain stem, hypothalamus, and intestine
or in islets from wild type mice (Figure 1B), consistent with previous
ﬁndings [38]. Correspondingly, LKB1 immunoreactivity was reduced
selectively in glucagon-positive cells in pancreatic sections from
aLKB1KO mice (Figure 1C). Moreover, total AMPK activity was reduced
by almost 40% in whole islets from these mice (60.5  8.1% of wild
type, p < 0.05; Figure 1D) compatible with a higher expression of
LKB1 in alpha than beta cells (ratio of Lkb1 to cyclophilin A mRNA:
0.36  0.09 in FACS-puriﬁed alpha vs. 0.11  0.03 in beta cells,
p < 0.05; Figure S1).
Similarly, we created mice deleted for both (aAMPKdKO) or single
(aAMPKa1KO and -a2KO) catalytic a-subunits selectively in pancre-
atic alpha cells by crossing either double AMPKa1 and a2 or single a-
isoform ﬂox’d mice with PPG-Cre deleter mice as above. Cre-mediated
recombination led to decreases in AMPK activity of w37%, w32%
and w27% in islets from aAMPKdKO, -a1KO and -a2KO mice,
respectively (Figure 1E), the more modest change in islets fromFigure 2: Male aLKB1KO mice display lowered fasting glucose and glucagon levels, and i
levels (B), and intraperitoneal glucose (C) and AICAR (D) tolerance of 8 week-old male mic
genotype. *p < 0.05, **p < 0.01, ***p < 0.001 between groups using unpaired two-tai
280 MOLECULAR METABOLISM 4 (2015) 277e286  2015 Published by ElseaAMPKdKO mice, possibly reﬂecting compensatory changes in the
expression or activity of the non-deleted isoform or one or more of the
12 other AMPK-related kinase(s) [39].
Consistent with the above demonstration that no or minimal recom-
bination occurred in enteroendocrine L-cells [38], fed plasma GLP-1
levels were identical between genotypes (19.2  4.8 pg/ml in
aLKB1KO mice, n ¼ 3e5 vs. 19.5  1.5 pg/ml in WT, n ¼ 3e5;
11.4  0.23 pg/ml, n ¼ 6 in aAMPKdKO mice vs 13.9  1.97 pg/ml,
n ¼ 4 in littermate controls). Likewise, supporting the ﬁnding that
deletion did not occur in ventromedial hypothalamic feeding centres
[11], we observed no signiﬁcant differences of body weight or daily
food intake of aLKB1KO or aAMPK KOs compared to wild-type lit-
termates (Figure S2aec).
3.2. Pancreatic alpha cell-selective deletion of LKB1, but not
AMPKa-subunits moderately lowers blood glucose and glucagon
levels
Examined at eight weeks of age, male aLKB1KO mice maintained
lower overnight fasting blood glucose levels (Figure 2A), while the
levels in aAMPKKOs and their littermate controls were comparable
(Figure S2def). Consistent with these ﬁndings, fasting plasma
glucagon levels were signiﬁcantly decreased after LKB1 deletion from
alpha cells (Figure 2B), with tendencies towards decreased plasma
glucagon in aAMPKa1KO and aAMPKdKO mice versus controls
(Figure S2g-i). Plasma insulin levels were not different betweenmproved glucose and AICAR tolerance. Fasting blood glucose (A) and plasma glucagon
e. Data are expressed as means  SEM; n ¼ 12e22 (A, B) and 7e12 (C, D) mice per
l t-tests (A, B, E, F) or two-way ANOVA with Sidak post hoc comparison (C, D).
vier GmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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genotypes in the fasted state (0.069  0.022 nmol/l in aLKB1KO,
n ¼ 5 vs. 0.078  0.019 nmol/l in WT, n ¼ 5). However, eight week-
old male aLKB1KO mice displayed signiﬁcantly improved tolerance to
intraperitoneal (IP) injection of glucose (Figure 2C), with comparable
insulin tolerance to wild type littermate controls (15 min post injection:
62.8  3.8% of initial value in aLKB1KO vs. 70.9  4.3% in wild
type; Figure S3a). None of the aAMPK KO mice displayed any alter-
ations in insulin (Figure S3b-d) or glucose tolerance (Figure S4a, c, e).
To examine the effects of LKB1 deletion in alpha cells in response to
hypoglycemia we ﬁrst challenged mice with the AMP mimetic ami-
noimidazole carboxamide ribonucleotide (AICAR) which activates
AMPK in extrapancreatic tissues (notably liver and muscle) contributing
to the effects of this agent to lower blood glucose levels [40]. As shown
in Figure 2D, AICAR sharply reduced blood glucose levels in overnight-
fasted eight week-old control male mice from 5.72  0.29 mmol/l at
0 min to 3.37  0.21 mmol/l at 40 min post injection (n ¼ 8). The
same manoeuvre lowered blood glucose even more dramatically, from
5.50 0.30 mmol/l to 2.70  0.22 mmol/l in aLKB1KO mice (51 3
vs. 40%  3% decrease in KO and wild type respectively, p ¼ 0.04).
However, plasma glucagon levels at 40 min post AICAR injection were
comparable between genotypes (354.0  62.3 pg/ml in KO vs.
501.7  141.9 pg/ml in WT, n ¼ 5; data not shown). These results
suggest that aLKB1KO mice might develop enhanced peripheral
sensitivity to AICAR rather than a blunted glucagon response. None of
the above differences were apparent in any of the aAMPK KO mice
(Figure S4b, d, f).
We next tested whether lower fasting glucagon levels, as observed in
aLKB1KO mice, may affect the expression of gluconeogenic genes in
the liver [41]. Of three genes (PEPCK, G6Pase and PGC-1a) examined
in 24 week-old male aLKB1KO versus control animals, none showed
signiﬁcant differences in expression between genotypes (Figure S4g).
L-arginine stimulates hepatic glucose production, and glucagon and
insulin secretion respectively from pancreatic alpha and beta cells [42].
In response to IP injection of L-arginine (3 g/kg) blood glucose levels rose
from 5.78  0.27 to 6.95  0.29 mmol/l in wild type mice and from
5.57  0.27 to 5.68  0.41 mmol/l in aLKB1KO mice 10 min after
injection (Figure S5a, KO vs. wild type, p¼ 0.007). Correspondingly, at
the same time point, plasma glucagon levels tended to be lower in
aLKB1KO (290.5  46.8 pg/ml) vs. wild type mice (389.9  38.9 pg/
ml; p¼ 0.07; Figure S5b). Plasma insulin levels at this time point were
not different between genotypes (Figure S5c).
3.3. Enhanced glucose infusion rates in aLKB1KO and
aAMPKa1KO mice versus controls under hyperinsulinemic-
hypoglycemic clamp and impaired glucagon release during insulin
tolerance tests
The above assessments of glucagon release in response to AICAR may
conceivably be complicated by impaired AMPK activation in the alpha
cell of aLKB1KO mice. We therefore further explored the impact of
deleting LKB1 or AMPKa isoforms in the alpha cell using
Hyperinsulinemic-hypoglycemic clamps. When aLKB1KO (Figure 3A,
B) or aAMPKa1KO (Figure 3C, D) mice were maintained under hy-
poglycemic conditions by constant intravenous insulin infusion,
signiﬁcantly higher glucose infusion rates were required in each case
to maintain w3 mmol/l glucose compared to the corresponding
littermate controls. Furthermore, and despite showing similar re-
sponses in terms of glycaemia during insulin tolerance tests
(Figure 3E), aLKB1KO animals showed impaired glucagon secretion
under these conditions (Figure 3F). Likewise, aAMPKa1KO mice
showed a strong tendency towards lowered glucagon secretion
(p ¼ 0.06at 30 min, Figure 3G,H). These data support the view thatMOLECULAR METABOLISM 4 (2015) 277e286  2015 Published by Elsevier GmbH. This is an open access
www.molecularmetabolism.comenhanced glucose disposal observed during clamps in each case was
likely due to impaired glucagon release.
No differences were observed in glucose disposal between aAMPKdKO
mice vs controls (Figure S6).
3.4. aLKB1KO and aAMPK KO mice display unaltered alpha cell
morphology, total mass and single cell size
The above results together suggested that deletion of LKB1 or AMPKa1
from the pancreatic alpha cell impairs glucose deprivation-induced
glucagon release in vivo. To determine whether this may be due to a
decrease in alpha cell mass, or in the size of individual alpha cells, we
measured these parameters by immunohistochemical analysis of
pancreatic sections from control, aLKB1KO, aAMPKa1KO or -dKO mice
and corresponding controls (Figure 4). This analysis revealed the ex-
pected distribution of cell types within islets in each case, with beta cells
concentrated in the core and alpha cells located mainly in the mantle
(Figure 4A). Quantiﬁcation of total alpha cell mass (Figure 4B, E, G) and of
single alpha cell size after labelling of the plasma membrane with E-
cadherin antibodies (Figure 4C) did not reveal signiﬁcant genotype-
dependent differences (Figure 4D, F, H). Correspondingly, growth factor
signalling through the phosphatidylinositol 30 kinase / Akt / mTOR
pathway, which is enhanced after deletion of LKB1 from beta cells [28],
was unaffected by the samemanipulation in alpha cells (Figure S7). Thus,
the degree of phosphorylation of ribosomal protein S6 or of its upstream
kinase, S6 kinase (both downstream targets of mTOR signalling) [43],
was not different in aLKB1KO versus control alpha cells (Figure S7).
3.5. Glucagon secretion is sensitized to inhibition by glucose in
islets isolated from aLKB1KO or aAMPKa1KO mice
The above studies suggested that glucagon secretion from alpha cells is
likely to be impaired in vivo after the deletion of LKB1 or AMPKa1 by
mechanisms which do not affect total alpha cell mass. To explore this
possibility, we investigated the effects of genomic deletion of these ki-
nases on the regulation of glucagon secretion from pancreatic alpha cells
using islets isolated from aLKB1 KO or aAMPK KO (-a1, -a2, dKO) mice.
Whereas glucagon release at a low, stimulatory concentration
(0.1 mmol/l) of glucose was comparable in islets from mice of all
genotypes, aLKB1KO or aAMPKa1KO mice released w2.5-fold less
glucagon in 30 min at 3 mmol/l glucose than the corresponding wild-
type islets (Figure 5A,B). Comparable rates of secretion were observed
from islets of all genotypes after incubation at 17 mmol/l glucose
(Figure 5). Indeed, glucagon secretion from islets of aLKB1KO or
aAMPKa1KO mice was maximally inhibited at 3 mmol/l glucose,
indicating enhanced sensitivity to the inhibitory effects of the sugar. By
contrast, the dose response to glucose of insulin secretion was not
different between wild-type or KO islets in either case (data not
shown), arguing against the possibility that the enhanced inhibitory
effect of 3 mmol/l glucose on glucagon secretion was due to altered
insulin or other beta cell secretion [1]. Furthermore, normal stimulatory
effects on glucagon secretion in response to 5 mmol/l epinephrine (at
17 mmol/l glucose) were preserved in aLKB1KO (Figure 5A) and in
aAMPKaKO (not shown) mouse islets.
Ablation of AMPKa2 (Figure 5C) or of both AMPKa isoforms (Figure 5D)
had no effect on the response of glucagon release to 3 mmol/l (vs
0.1 mmol/l) glucose though we noted that the response to 17 mmol/l
glucose was impaired after the loss of AMPKa2 (Figure 5C).
4. DISCUSSION
The overall aim of the present study was to explore the cell-
autonomous role of LKB1 and of two key downstream kinases in thearticle under the CC BY license (http://creativecommons.org/licenses/by/3.0/). 281
Figure 3: Both aLKB1KO and aAMPKa1KO mice exhibit enhanced glucose sensitivity during hyperinsulinemic-hypoglycemic clamps and impaired glucagon release during insulin
tolerance tests. Blood glucose levels (A, C) and glucose infusion rates (B, D) of aLKB1KO (A, B) or aAMPKa1KO mice (C, D) and their wild type littermate controls during insulin
(0.6 U/kg/h) and glucose (20%) co-infusion. Arrow heads with dashed lines, bolus insulin infusion; arrow heads with solid lines, constant insulin (0.6 U/kg/h) infusion. (E,F)
Changes in plasma glucose (E) and glucagon (F) after injection of 0.75 U/Kg into wild type or aLKB1KO mice. (G,H) as (E,F), using AMPKdKO mice and controls. Data are expressed
as means  SEM; n ¼ 4e7 mice per genotype. *p < 0.05, **p < 0.01, ***p < 0.001 between groups by two-way ANOVA with Sidak post hoc comparison (AeD) or two-tailed
Student’s t-test with Bonferroni correction (EeH).
Original articlecontrol of glucagon production in the mouse. The concept that mod-
ulation of glucagon levels may represent a useful therapeutic approach
to some forms of diabetes has existed for many years [44] and was
further supported recently by two separate studies in which mice null
for glucagon receptors were shown to be resistant to beta cell
destruction by streptozotocin induced diabetes [45,46]. On the other
hand, substantial (>90%) [38] ablation of alpha cell mass using
diphtheria toxin has relatively modest effects on glucose homoeostasis
suggesting alpha cell plasticity under some conditions.
4.1. PPG-Cre expression is localized in alpha cells
The present (Figure 1A) and previous [33] ﬁndings suggest that PPG-Cre
leads to recombination with high selectivity, but with limited efﬁciency
(w45%) in alpha cells. Despite this, apparent AMPK activity was282 MOLECULAR METABOLISM 4 (2015) 277e286  2015 Published by Elsemarkedly (40%) reduced, presumably reﬂecting the enrichment of LKB1
in alpha and other islet cells [22] and possibly differences between cell
types in the expression, stability or regulation of AMPK subunits, or other
regulatory enzymes (phosphatases, e.g.). We note that the potential loss
of RFP ﬂuorescence during the staining procedure, as well as differ-
ences in recombination efﬁciency at the Rosa26 versus the LKB1 loci,
means that these measurements may in any case under (or over-)
estimate of the degree of recombination at the latter.
Nonetheless, we observed changes in glucagon secretion in mice
deleted for LKB1 or AMPKa1 with this strategy, suggesting an indis-
pensable role of these kinases in the pancreatic alpha cell. Further-
more, it might be speculated that recombination targets a subset of
alpha cells which display a greater degree of control of the whole alpha
cell population than others, i.e. that these cells play a “hub” orvier GmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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Figure 4: aLKB1KO and aAMPKa1KO, -dKO mouse islets show normal alpha cell morphology, size and mass. (A) Representative immunostaining of pancreatic sections using
guinea pig anti-insulin (green, 1:200) and mouse anti-glucagon antibodies (Red, 1:2000). (B, E, G) Quantitation of relative a- and b-cell mass based on immunostaining of
pancreatic sections. Relative islet cell mass was calculated by expressing total glucagon (a-cell)- or insulin (b-cell)-positive area as a proportion of total autoﬂuorescent pancreatic
area. Three to four sections per pancreas were analyzed. (C) Representative glucagon (red) and E-cadherin (green) staining of pancreatic sections. Nuclei are shown by DAPI (blue)
staining. (D, F, H) Quantiﬁcation of single alpha and beta cell size. Data are expressed as means  SEM. n ¼ 5 mice per genotype. Scale bar, 40 mm. No statistically signiﬁcant
changes were detected (two-tailed t-test with Bonferroni correction).“pacemaker” function [47]. Although a comparison with the effects of
more complete deletion of LKB1 or AMPKa1 throughout the alpha cell
population would test this hypothesis, alternative alpha cell-targeting
strategies, e.g. the “iGlu.Cre” mouse [35], can lead to off-target ef-
fects [48].
It is relevant to mention that our studies were limited to exami-
nation of the phenotype of animals maintained on the low fat (w7%
of calories) diet usually used in mouse studies, a diet with a fat
value much lower than that of the typical westernized human diet
(20e25% fat) [49]. Future studies of the knockout models gener-
ated here, both in the context of “humanized” diets and after
breeding to backgrounds susceptible to diabetes (db/db, e.g.), may
also provide interesting information on the role of LKB1 (and AMPK)MOLECULAR METABOLISM 4 (2015) 277e286  2015 Published by Elsevier GmbH. This is an open access
www.molecularmetabolism.comin controlling glucagon secretion from alpha cells in pathological
states in man.
Finally, and although the present ﬁndings might seem at odds with
the fact that deletion of the majority of the alpha cell complement
exerts minor effects on glucose tolerance [38], we note that
the effects of hypoglycemia were not examined in this earlier
study.
4.2. Deletion of LKB1 in alpha cells does not alter cell size or total
pancreatic alpha cell mass
Inactivation of LKB1 selectively in pancreatic beta cells dramatically
enhances total insulin output and beta cell mass [26,28]. These
changes are accompanied by up-regulation of mTOR signalling [26earticle under the CC BY license (http://creativecommons.org/licenses/by/3.0/). 283
Figure 5: aLKB1 KO and aAMPKa1, -dKO mouse islets secrete less glucagon in response to low (3 mmol/l) glucose. Glucagon secretion from 12 size-matched islets isolated from
aLKB1KO (A), a AMPKa1KO (B), a2KO and (C), dKO mice (D) and their respective wild type littermate controls, statically incubated for 1 h at 0.1 mmol/l (white bar), 3 mmol/l (grey
bars), 17 mmol/l (black bars) glucose, or 17 mmol/l glucose in the presence of 5 mmol/l epinephrine. Eight week-old male mice were used. Data are expressed as means  SEM;
n ¼ 3e5. *p < 0.05, **p < 0.01, ***p < 0.001 using two-way ANOVA followed by Sidak post-hoc comparison.
Original article28]. Strikingly, deletion of LKB1 from alpha cells here did not affect
overall pancreatic alpha cell mass or individual alpha cell size
(Figure 4AeD). Such changes, therefore, cannot explain the observed
decreases of glucagon output (Figure 2B) and counter-regulation
(Figures 2D and 3) seen in vivo in aLKB1KO mice. Analysis of
phospho-S6 kinase levels by Western blotting, or staining for phospho-
S6 ribosomal protein (rpS6), did not reveal changes in these param-
eters in alpha cells from aLKB1KO mice compared to controls
(Figure S7). Thus, attenuation of mTOR signalling by LKB1 appears to
be absent from alpha cells for reasons that are presently unclear.
4.3. LKB1 regulates glucagon secretion from pancreatic alpha cells
Themechanisms throughwhich glucose regulates glucagon release from
the pancreatic alpha cell are still incompletely understood. As glucose
levels fall, the partial opening of ATP-dependent Kþ channels and of low
voltage-gated Ca2þ and Naþ channels has been proposed to activate high
voltage-gated Ca2þ channels to stimulate glucagon secretion [50]. In an
alternative model [51], diminished ATP-dependent Ca2þ accumulation by
the endoplasmic reticulum may modulate Ca2þ inﬂux.
We show here that mice null for LKB1 in pancreatic alpha cells exhibit
modestly reduced plasma glucose and glucagon levels in vivo
(Figure 2A,B) and enhanced insulin sensitivity during hypoglycemic
clamps (Figure 3A,B), likely due to reduced glucagon secretion from
pancreatic alpha cells. Measurement of portal vein glucagon levels
during clamps, which better reﬂect changes in glucagon secretion
from the pancreas than systemic concentrations [52], present a
signiﬁcant technical challenge in the mouse. Moreover, measurement
of glucagon from tail vein samples requires the collection of relatively
large blood volumes, known to cause substantial increases in cate-
cholamine levels [53]. Consequently, such measurements were not
performed here. Nonetheless, examined in isolated islets, inactivation
of LKB1 unmasked a clear inhibitory effect of 3 mmol/l glucose on
glucagon secretion, a concentration of the sugar at which release
was unaffected (versus the rate of release at 0.1 mmol/l glucose) in284 MOLECULAR METABOLISM 4 (2015) 277e286  2015 Published by Elsecontrol islets (Figure 5A). This result is in sharp contrast to the effects
of inactivating LKB1 in pancreatic beta cells, where large increases
(after one week of deletion in adults) [26,27] or mild decreases
(inactivation from E9-11) [28] are seen in glucose-stimulated insulin
secretion.
As discussed above, the present results indicate that the absence of
LKB1 from alpha cells elicits a marked left-shift in sensitivity to
glucose. The mechanism(s) involved will require further investigation
but may involve either longer term changes in the expression of key
transporters and enzymes involved in glucose sensing (e.g. glucoki-
nase, Ca2þ channels) or a more acute role of LKB1 in mediating the
metabolic responses to the sugar, as previously proposed [22].
Detailed transcriptomic and proteomic analyses of puriﬁed LKB1-null
alpha cells will be required to address the former possibility. Of
note, since responses to L-arginine were abnormally reduced in
aLKB1KO mice compared to controls (Figure S5b) it seems likely that
late events in the triggering of glucagon secretion (e.g. secretory
granule fusion at the plasma membrane) require LKB1 and/or its
downstream targets.
AMPK is the best studied downstream target of LKB1 and plays key
roles in the responses to the anti-diabetic drug, metformin [54]. In
contrast to the situation in the beta cell [28,30] we reveal here that
AMPKa1 is likely, at least in part, to mediate the effects of LKB1 on
glucagon secretion in the alpha cell (Figures 3 and 5). Thus, elimination
of AMPKa1 partly mimicked the effects of LKB1 deletion of counter-
regulatory responses (Figure 3) and on the control of glucagon
release (Figure 5), while loss of AMPKa2 exerted more subtle effects.
Paradoxically, elimination of both isoforms had no, or minimal, effects
on the above, suggesting that compensatory increases in the expres-
sion of other genes may normalize glucagon production. Of note, each
of the AMPK-related kinases has similar substrate preferences to the
canonical AMPK kinases but is regulated by distinct upstream mech-
anisms. While MARK2 [26] has been implicated in the effects of LKB1 in
beta cells, SIK2 elimination impairs insulin release by permitting thevier GmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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accumulation of the CDK5 activator CDK5R1 (p35) and inhibition of
Ca2þ entry [55]. Loss of SIK2 activity in LKB1-depleted alpha cells may
thus lead to defective glucagon release in a similar manner. Further-
more, up-regulation of this enzyme in aAMPKdKO islets could
conceivably contribute to the normalization of responses in the latter
model. Future studies will be needed to test these possibilities.
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